5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Performance of clinical signs and symptoms, rapid and reference laboratory diagnostic tests for diagnosis of human African trypanosomiasis by passive screening in Guinea: a prospective diagnostic accuracy study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Passive diagnosis of human African trypanosomiasis (HAT) at the health facility level is a major component of HAT control in Guinea. We examined which clinical signs and symptoms are associated with HAT, and assessed the performance of selected clinical presentations, of rapid diagnostic tests (RDT), and of reference laboratory tests on dried blood spots (DBS) for diagnosing HAT in Guinea.

          Method

          The study took place in 14 health facilities in Guinea, where 2345 clinical suspects were tested with RDTs (HAT Sero- K-Set, rHAT Sero-Strip, and SD Bioline HAT). Seropositives underwent parasitological examination (reference test) to confirm HAT and their DBS were tested in indirect enzyme-linked immunoassay (ELISA)/ Trypanosoma brucei gambiense, trypanolysis, Loopamp Trypanosoma brucei Detection kit (LAMP) and m18S quantitative PCR (qPCR). Multivariable regression analysis assessed association of clinical presentation with HAT. Sensitivity, specificity, positive and negative predictive values of key clinical presentations, of the RDTs and of the DBS tests for HAT diagnosis were determined.

          Results

          The HAT prevalence, as confirmed parasitologically, was 2.0% (48/2345, 95% CI: 1.5–2.7%). Odds ratios ( OR) for HAT were increased for participants with swollen lymph nodes ( OR = 96.7, 95% CI: 20.7–452.0), important weight loss ( OR = 20.4, 95% CI: 7.05–58.9), severe itching ( OR = 45.9, 95% CI: 7.3–288.7) or motor disorders ( OR = 4.5, 95% CI: 0.89–22.5). Presence of at least one of these clinical presentations was 75.6% (95% CI: 73.8–77.4%) specific and 97.9% (95% CI: 88.9–99.9%) sensitive for HAT. HAT Sero- K-Set, rHAT Sero-Strip, and SD Bioline HAT were respectively 97.5% (95% CI: 96.8–98.1%), 99.4% (95% CI: 99.0–99.7%) and 97.9% (95% CI: 97.2–98.4%) specific, and 100% (95% CI: 92.5–100.0%), 59.6% (95% CI: 44.3–73.3%) and 93.8% (95% CI: 82.8–98.7%) sensitive for HAT. The RDT’s positive and negative predictive values ranged from 45.2–66.7% and 99.2–100% respectively. All DBS tests had specificities ≥ 92.9%. While LAMP and m18S qPCR sensitivities were below 50%, trypanolysis and ELISA/ T.b. gambiense had sensitivities of 85.3% (95% CI: 68.9–95.0%) and 67.6% (95% CI: 49.5–82.6%).

          Conclusions

          Presence of swollen lymph nodes, important weight loss, severe itching or motor disorders are simple but accurate clinical criteria for HAT referral in HAT endemic areas in Guinea. Diagnostic performances of HAT Sero- K-Set and SD Bioline HAT are sufficient for referring positives to microscopy. Trypanolysis on DBS may discriminate HAT patients from false RDT positives.

          Trial registration The trial was registered under NCT03356665 in clinicaltrials.gov (November 29, 2017, retrospectively registered https://clinicaltrials.gov/ct2/show/NCT03356665)

          Graphical Abstract

          Related collections

          Most cited references39

          • Record: found
          • Abstract: not found
          • Article: not found

          The Measurement of Observer Agreement for Categorical Data

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical aspects of 2541 patients with second stage human African trypanosomiasis.

            The clinical symptoms and signs of patients with second stage HAT are described for a large cohort of patients treated in a prospective multicentre, multinational study. Special emphasis is given to the influence of disease stage (duration, number of WBC in CSF) and patient age to the clinical picture. Even though the frequencies of symptoms and signs are highly variable between centres, the clinical picture of the disease is similar for all countries. Headache (78.7%), sleeping disorder (74.4%) and lymphadenopathy (56.1%) are the most frequent symptoms and signs and they are similar for all stages of the disease. Lymphadenopathy tends to be highest in the advanced second stage (59.0%). The neurological and psychiatric symptoms increase significantly with the number of WBC in the CSF indicating the stage of progression of the disease. Pruritus is observed in all stages and increases with the number of WBC in CSF from 30 to 55%. In children younger than 7 years, lymphadenopathy is less frequently reported (11.8-37.3%) than in older children or adults (56.4-61.2%). Fever is most frequently reported in children between 2 and 14 years of age (26.1-28.7%) and malnutrition is significantly more frequently observed in children of all ages (43-56%) than in adults (23.5%).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for Sleeping Sickness Diagnosis and Staging

              Human African trypanosomiasis (HAT), or sleeping sickness, is caused by two subspecies of the protozoan parasite Trypanosoma brucei (T.b.) and transmitted through tsetse flies (Glossina sp.). T.b. gambiense occurs from West to Central sub-Sahara Africa, while T.b. rhodesiense is endemic in East sub-Sahara Africa. Other closely related taxa (T.b. brucei, T. evansi, T. equiperdum, T. congolense, T. vivax) cause animal African trypanosomiases in domestic animals like cattle, horse, camel, goat, sheep, and buffalo in Africa, Latin America, Europe, and Asia [1]. Approximately 10,000 sleeping sickness patients are diagnosed and treated each year [2]. This is only a fraction of those carrying this lethal infection since (i) the population at risk lives mainly in remote areas outside the action radius of health centres or mobile teams, and (ii) the diagnostic tests suffer from limited sensitivity [3],[4]. There is a consensus to (i) only treat patients with confirmed diagnosis, i.e., in whom the parasite has been demonstrated, except in particular situations, and (ii) to examine the cerebrospinal fluid (CSF) for white blood cell counts and the presence of trypanosomes in order to decide which drugs to administer. To determine whether a patient is cured, examination of CSF is repeated each semester for up to 2 years [4]. In T.b. gambiense sleeping sickness, general low parasite loads necessitate the use of concentration techniques to reveal infection. Capillary tube centrifugation (CTC, WOO) [5], quantitative buffy coat (QBC) [6], and mini anion exchange centrifugation technique (mAECT) [7] are applied on blood. mAECT is the most sensitive method for trypanosome detection in blood and is based on a purification technique first described by Lanham et al. and later adapted for diagnosis of sleeping sickness and of animal infections with T. brucei and T. evansi [7]–[10]. In mAECT, trypanosomes are separated from 350 µl of blood by anion exchange chromatography on diethylaminoethyl cellulose (DEAE). Eluted trypanosomes are then concentrated by low speed centrifugation followed by direct microscopic examination of the sediment in a transparent collector tube. The large volume of blood examined allows detection of fewer than 50 trypanosomes/ml. For sensitive detection of trypanosomes in CSF, single and double centrifugation (DC) and modified single centrifugation (MSC) are applied, with MSC being easier to perform and at least as sensitive as DC [11]. For several years, mAECT was produced at the Projet de Recherches Cliniques sur la Trypanosomiase (PRCT) in Daloa, Côte d'Ivoire, with financial support from the World Health Organization (WHO), and then for some time at Institut Pierre Richet (IPR) in Bouaké, Côte d'Ivoire. The PRCT model is still produced on demand in this country (B. Miezan, personal commmunication). Several attempts to establish a production unit elsewhere were discontinued. At the request of the Belgian Technical Cooperation (BTC) for the Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA) in the Democratic Republic of the Congo (DRC), the Institute of Tropical Medicine (ITM, Belgium) and the Institut National de Recherche Biomédicale (INRB, DRC) developed a modified version of the mAECT. With financial support from the Belgian Directorate General for Development Cooperation and WHO, production at INRB started in 2003. At the end of 2005, production stopped since raw material for the 9-mm diameter glass collector tube was not commercially available anymore. From 2006 on, with support from the Foundation for Innovative New Diagnostics (FIND), the column rack, microscope viewing chamber, and collector tube were redesigned. Important advantages of the new collector tube and the viewing chamber are their robustness and the fact that microscopic examination of the sediment is possible without mounting the tip of the collector tube under water (Figures 1– 3). Improvements were made to the packing trays (Figure S1), filter material (Figure S2), sterilisation procedure, and instruction leaflets. In addition, the production infrastructure at INRB and the quality control system were upgraded. Actually, quality control is performed internally at INRB and externally at ITM before a batch is released. Detailed production standard operating procedures were written and are collated in an mAECT handbook that can be found on the FIND Web site [12]. 10.1371/journal.pntd.0000471.g001 Figure 1 Column rack with mounted columns and trypanosomes being eluted from the blood in the collector tubes. 10.1371/journal.pntd.0000471.g002 Figure 2 Collector tube mounted in the mAECT viewing chamber under the microscope. 10.1371/journal.pntd.0000471.g003 Figure 3 Detail of collector tube tip. In 2007, a comparison between the first model of mAECT produced at INRB and the PRCT model was carried out at the Centre International de Recherche-Développement sur l'Elevage en zone Sub-humide (CIRDES) in Bobo-Dioulasso, Burkina Faso, on 198 columns of each model. Columns received 350 µl of human blood containing on average 35 T.b. gambiense trypanosomes (100 trypanosomes per ml of blood). The time to run a column was recorded and trypanosomes in each collector tube were counted by two independent observers. Averages were compared using paired t-test and showed a significantly shorter run time for the INRB than the PRCT model (29 and 42 min, respectively, p<0.0001), which is explained by the fact that in the INRB model, no glucose should be added before applying the blood. In addition, more trypanosomes were recovered by the INRB than by the PRCT model (5.85 and 4.92, respectively, p<0.005). After changing the filter material in 2008, the second INRB model was compared with the previous one by the same CIRDES experts on 195 columns of each type. The second model runs faster than the first (21 and 33 min, respectively, p<0.0001) and showed higher average trypanosome numbers (4.43 and 1.76, respectively, p<0.0001). The lower average trypanosome numbers counted with the first model compared to the previous comparison is probably caused by the still unexplained fact that the number of recovered trypanosomes seems to be blood donor dependent. The INRB mAECT kit consists of two cardboard boxes. One contains 20 mAECT columns best stored at 4°C–8°C, although tests are stable for 12 months at a maximum of 37°C. The other contains 20 collector tubes, 20 centrifugation tubes, 20 transfer pipettes, and the instruction leaflet (available in English, French, and Portuguese). Specifications of the kit are given in Box 1. Box 1. Three Advantages and Three Disadvantages for the New mAECT Model Advantages Analytical sensitivity <50 trypanosomes per ml of blood at only €3 per test. Robustness and no need to mount collector tube in water for microscopic examination. Applicable in field conditions. Disadvantages Need for specific material and centrifuge. Limited stability since the glucose is now incorporated in the column buffer (maximum 1 year at 37°C). Qualified personnel needed to perform the test. In the original MSC test on CSF described by Miezan et al., 2-ml glass pasteur pipettes are used as collector tubes and are examined after mounting the tip under water [11]. With its 4 ml of volume and no need for mounting under water, the new plastic mAECT collector tube is expected to increase the sensitivity and the robustness of MSC on CSF, although a formal comparative test still has to be performed. An MSC kit for 20 tests with instruction leaflets in English, French, or Portuguese is now also available from INRB. Specifications of the kit are given in Box 2. Box 2. Three Advantages and Three Disadvantages for the New MSC Model Advantages Analytical sensitivity <2 trypanosomes per ml of CSF at only €0.5 per test. Short test time (<15 minutes). Few manipulations. Disadvantages Need for specific material and centrifuge. CSF sediment cannot be recuperated for other tests. Interference of CSF white blood cells possible, especially at high cell counts. mAECT and MSC kits can be ordered at INRB. For prices and delivery conditions, contact mumbadieudonne@yahoo.fr. Additional information is available on the FIND Web site at http://www.finddiagnostics.org. The mAECT and MSC tests are used by diverse organisations and institutes in their HAT control activities and in clinical investigations. Current clients are the National HAT Control Programme in DRC, the World Health Organization, Institute of Tropical Medicine Antwerp, Swiss Tropical Institute, Drugs for Neglected Diseases Initiative, Médecins Sans Frontières, Medische Missie Samenwerking, Institut de Recherche au Développement, and Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale. Supporting Information Figure S1 Box with Ten mAECT Columns (0.26 MB PDF) Click here for additional data file. Figure S2 Elution of T. brucei Parasites from Blood with the mAECT Columns (0.27 MB PDF) Click here for additional data file.
                Bookmark

                Author and article information

                Contributors
                veerle.lejon@ird.fr
                Journal
                Infect Dis Poverty
                Infect Dis Poverty
                Infectious Diseases of Poverty
                BioMed Central (London )
                2095-5162
                2049-9957
                20 March 2023
                20 March 2023
                2023
                : 12
                : 22
                Affiliations
                [1 ]Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea
                [2 ]GRID grid.419369.0, ISNI 0000 0000 9378 4481, International Livestock Research Institute, ; Nairobi, Kenya
                [3 ]GRID grid.10025.36, ISNI 0000 0004 1936 8470, Institute of Infection, Veterinary and Ecological Sciences, , University of Liverpool, ; Liverpool, UK
                [4 ]GRID grid.457337.1, ISNI 0000 0004 0564 0509, Clinical Research Unit of Nanoro, , Institute for Health Science Research (IRSS), ; Ouagadougou, Burkina Faso
                [5 ]GRID grid.423769.d, ISNI 0000 0004 7592 2050, Vector-Borne Diseases and Biodiversity Unit, , International Research and Development Center on Livestock in Sub-Humid Areas (CIRDES), ; Bobo-Dioulasso, Burkina Faso
                [6 ]GRID grid.442667.5, ISNI 0000 0004 0474 2212, Unit of Research and Training in Life and Earth Sciences, , University of Nazi Boni, ; Bobo-Dioulasso, Burkina Faso
                [7 ]GRID grid.11505.30, ISNI 0000 0001 2153 5088, Department of Biomedical Sciences, , Institute of Tropical Medicine, ; Antwerp, Belgium
                [8 ]GRID grid.121334.6, ISNI 0000 0001 2097 0141, UMR Intertryp IRD-CIRAD, , French National Research Institute for Sustainable Development (IRD), University of Montpellier, ; Montpellier, France
                Author information
                http://orcid.org/0000-0002-6795-0962
                Article
                1076
                10.1186/s40249-023-01076-1
                10026442
                36941656
                705ff729-f45c-4b18-a897-e2545a4f5567
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 30 November 2022
                : 6 March 2023
                Funding
                Funded by: EDCTP2
                Award ID: DRIA-2014-306-DiTECT-HAT
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2023

                human african trypanosomiasis,trypanosoma brucei gambiense,diagnosis,clinical,rapid diagnostic test,sensitivity,specificity,dried blood spot,trypanolysis

                Comments

                Comment on this article